Tela Bio, Inc. ( (TELA) ) has released its Q2 earnings. Here is a breakdown of the information Tela Bio, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TELA Bio, Inc. is a commercial-stage medical technology company dedicated to providing innovative soft-tissue reconstruction solutions, focusing on optimizing clinical outcomes while minimizing the use of permanent synthetic materials.
In its second quarter of 2025, TELA Bio reported a revenue of $20.2 million, marking a 26% increase compared to the same period in 2024. This growth was driven by increased demand for its OviTex® and OviTex PRS Reinforced Tissue Matrix products and the expansion of its European market presence.
Key financial metrics revealed a gross profit of $14.1 million, representing 69.8% of revenue, and a reduction in net loss to $9.9 million from $12.6 million in the previous year. The company also appointed Jeffrey Blizard as President to enhance commercial leadership and announced the European launch of OviTex Inguinal for hernia repair.
Looking ahead, TELA Bio reiterated its full-year 2025 revenue guidance of $85.0 million to $88.0 million, projecting a growth rate of 23% to 27% over 2024. The company remains focused on optimizing its sales force and expanding its market reach to foster sustainable growth.